birthcontrol for men

Overview of Male Contraception Development

• Introduction: The discussion focuses on the ongoing development of male contraceptives, particularly the NES/T gel, a novel topical formulation.

Alex Springer's Routine

• Daily Routine: Alex Springer, a participant in the NES/T trial, incorporates contraceptive use into his daily routine after taking a shower and applying gel.

• Personal Context: Springer and his partner, Mel Hopkins, choose this method due to specific health considerations.

• Importance of NES/T: Highlights the gel's role as effective male birth control in their current family planning.

NES/T Gel Trial Details

• Trial Description: Phase 2 trial of NES/T gel combining a synthetic progestin (Nestorone) and testosterone to suppress sperm production.

• Efficacy: Much higher efficacy than expected; possibly lower failure rates than traditional birth control pills.

• Comparison to Past Trials: Past hormonal contraceptives targeting sperm have not made it to market due to side effects and efficacy concerns.

• Significant and Unique Aspects: NES/T is self-administered, not an injection, and incorporates mental health checks.

Demand for Male Contraceptive Options

• Rising Demand: Increased calls for male birth control options amplified by the US Supreme Court's decision regarding abortion rights.

• Broader Context: Contraception concerns affect diverse gender identities, including transgender men and nonbinary individuals.

Non-Hormonal Contraceptive Options

• Interest in Alternatives: Many seek non-hormonal methods to avoid side effects associated with hormonal drugs.

• Efficacy Concerns: 10-15% of users may not achieve effective sperm suppression with hormonal methods due to various factors.

• Clinical Trial Progress: Potential non-hormonal candidates approaching human trials, alongside ongoing hormonal candidates like NES/T.

Historical Context of Contraceptive Development

• Historical Stigma: Contraceptive discussions were taboo when hormonal birth control for women emerged in the 1960s.

• Shift in Demand: Increased demand and recognition of shared reproductive responsibilities among couples in recent studies.

Current Attitude Toward Male Contraceptives

• Survey Findings: Various surveys indicate significant male interest in hormonal contraception; 44-83% indicated willingness to use a hormonal male contraceptive.

• Gender Equality: Both men and women express interest in male contraceptive options and improved family planning.

Mechanisms of Historical Hormonal Methods

• Functionality of Hormonal Options: Hormonal contraceptives work by inhibiting sperm production but can present side effects across the body.

• Challenges with Hormonal Side Effects: Some hormonal methods have faced failures in trials due to mood disorder side effects.

Promising Non-Hormonal Candidates

• Non-Hormonal Targets: Candidates targeting specific proteins in the sperm lifecycle to avoid the pitfalls of hormonal methods.

• Mechanistic Variety: Different candidates focus on sperm production, motility, and functionality:

  • YCT-529: Targets RAR-α, blocking retinoic acid to impede sperm production.

  • CatSper Research: Focused on a protein essential for sperm motility to directly inhibit movement.

  • EPPIN Inhibitor (EP055): Blocks functionalities necessary for sperm activation.

  • On-Demand Options: Work on drugs like soluble adenylyl cyclase inhibitors for rapid cessation of sperm motility immediately before intercourse.

Obstacles and Concerns in Development

• Potential Toxicity: Risks of non-hormonal contraceptive drugs affecting broader biological systems, leading to unintended side effects.

• Regulatory Challenges: Tougher approval pathways for male contraceptives due to lower acceptance of perceived risks compared to life-threatening conditions.

• Need for Market Validation: Companies often hesitant due to litigation risks associated with contraceptives have historically faced.

Market Potential and Future Outlook

• Market Analysis: Potential significant market given the number of men eligible for contraception.

• Clinical Path Forward: Optimism for the upcoming years with human trials anticipated for both hormonal and non-hormonal options.

• Community Enthusiasm: Increased interest noted from participants and potential users eager for more contraceptive choices and responsibilities.